Table 3.

Exposure to Treatment and Adherence to Treatment

a) Main period
	Somapacitan	Daily GH	Placebo
	(N = 120)	(N = 119)	(N = 61)
Exposure to treatment, days
Mean	232 (36.2)	226 (48.0)	228 (36.1)
Median	238	238	238
Treatment dose, mg, mean (SD)	2.56 (1.48) mg/week Equivalent to 0.37 mg/day	0.33 (0.19) mg/day Equivalent to 2.31 mg/week	2.20 (0.74) mg/week Equivalent to 0.31 mg/day
Mean adherence, %	95.5	90.6	93.9
b) Extension period
	Somapacitan/ Somapacitan	Daily GH/ Daily GH	Placebo/ Somapacitan	Daily GH/ Somapacitan
	(N = 114)	(N = 52)	(N = 55)	(N = 51)
Exposure to treatment, days
Mean	355 (52.4)	349 (48.8)	357 (40.4)	343 (76.6)
Median	364	364	364	364
Treatment dose in extension, mg, mean (SD)	2.35 (1.30) mg/week Equivalent to 0.34 mg/day	0.28 (0.16) mg/day Equivalent to 1.96 mg/week	2.61 (1.40) mg/week Equivalent to 0.37 mg/day	2.66 (1.37) mg/week Equivalent to 0.38 mg/day
Mean adherence during extension, %	94.7	91.9	89.8	94.7